Results from two studies suggest that the current US Preventive Services Task Force lung cancer screening criteria may exclude certain individuals who could benefit from screening.
Brain metastases are a common complication of lung cancer and are associated with significant morbidity and mortality. In this video, Manmeet Ahluwalia provides a neuro-oncologist's perspective on managing lung cancer patients who develop these metastases.
These videos were made possible by independent educational funding provided by AstraZeneca.
Veeru Kasivisvanathan explains the background and clinical implications of the PRECISION trial, which tested whether using multiparametric MRI with a targeted biopsy was noninferior to standard transrectal ultrasonography–guided biopsy in the detection of clinically significant prostate cancer.
Findings from an extended follow-up of the National Lung Screening Trial maintain that low-dose computed tomography screening significantly reduces risk for lung cancer death versus chest radiography screening among high-risk current and former smokers.
Rates of active surveillance or watchful waiting among younger men with low‐risk prostate cancer have quadrupled in recent years but remain below those for older men, despite no apparent increased mortality risk, research shows.
Combining abiraterone acetate with a relatively high dose of prednisone or dexamethasone may reduce mineralocorticoid excess toxic effects, but can result in increased metabolic toxicity, study data show.
Single-agent vemurafenib has demonstrated promising antitumor activity against non-small-cell lung cancer harboring BRAF V600E mutations in the VE-BASKET trial.
Results from two studies suggest that the current US Preventive Services Task Force lung cancer screening criteria may exclude certain individuals who could benefit from screening.
An analysis of oncology drugs approved by the US FDA shows that nearly half have not shown improvements in either overall survival or patient-reported outcomes.
Meet the Editorial Board
Our international Editorial Board members Dr Fiona Blackhall (Christie Hospital, Manchester, UK) and Dr Axel Merseburger (University Hospital Schleswig-Holstein, Germany) work closely with the editorial team to highlight gaps in coverage and select topics to feature on this digital platform.
Why register? Medicine Matters oncology is a free resource providing the latest news and clinical guidance
Register today and receive updates directly to your inbox! Medicine Matters oncology has been specifically developed for the time-limited healthcare professional who is looking for a single resource providing credible information on current practice and the latest advances in oncology. Already registered? Log in now to unlock your access.
